Gonadorelin
Also referenced as: GnRH, LHRH, Factrel
Synthetic gonadotropin-releasing hormone, used diagnostically and increasingly in compounded hormonal practice.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- FDA Approved for Specific Indication
Gonadorelin has held approval for diagnostic evaluation of gonadotropin function. It is now often compounded for fertility-related use alongside testosterone therapy, which is not an approved indication.
- Human data
- Yes
No registered clinical trials identified
- Last reviewed
- September 1, 2026
Overview
Gonadorelin is identical to natural GnRH, the hypothalamic decapeptide that drives pituitary LH and FSH release in pulses.
Its pharmacology is unambiguous; the question is whether the newer compounded uses discussed in men's health clinics are supported by outcome evidence. Largely, they are not.
Why It's Being Studied
- Diagnostic assessment of pituitary gonadotropin reserve.
- Maintenance of testicular function during exogenous testosterone use (compounded, off-label).
- Fertility and hypogonadotropic hypogonadism.
Mechanism of Action
It is the hormone signal that tells the pituitary to stimulate the testes or ovaries, given in short pulses.
Gonadorelin binds pituitary GnRH receptors, triggering LH and FSH release. Pulsatile administration preserves receptor sensitivity; continuous exposure causes receptor downregulation and gonadotropin suppression — the basis of GnRH agonist therapy in hormone-sensitive disease.
Research Areas & Routes Studied
- Gonadotropin function
- Fertility
- Testicular function
- Subcutaneous injection
- Intravenous (diagnostic)
Evidence Summary
Long-standing human use as a diagnostic and fertility agent with established pharmacology, though modern outcome trials for newer community uses are absent.
Human clinical evidence
- Diagnostic use is well established in endocrinology.
- Evidence for maintaining fertility during testosterone therapy relies heavily on extrapolation and clinical experience rather than randomised trials.
Observational evidence
- Compounded clinical use is common but poorly documented in the literature.
Reported Adverse Events in Research
- Headache, nausea, flushing, abdominal discomfort.
- Injection-site reactions; rare hypersensitivity.
- Continuous rather than pulsatile exposure can suppress rather than stimulate the axis.
Limitations of Current Evidence
- Short half-life makes dosing schedules critical and hard to standardise.
- Randomised evidence for current off-label uses is lacking.
Why It Is Used
- Sexual Health
Libido and Sexual Function
One of the few categories where the leading compound is FDA approved — and where its close relative is a clear example of what unselective signalling costs.
Read the case study
Research References
- Prescribing label
Gonadorelin diagnostic labelling records
- Narrative review
GnRH physiology and pulsatile administration